N/A N=48 Noninvasive Monitoring of Uterine Electrical Activity and Fetal Heart Rate: A New External Monitoring Device
Contraction
Primary: Continuity in Readings of Contractions — 0; 0 Number of minutes — p=0.75
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=14 A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 474121 in the Blood
Healthy
Primary: Area Under the Concentration-time Curve of BI 474121 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-∞) — NA; NA hours*nanomole/Liter
Phase 2 N=109 A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
Advanced or Metastatic Solid Tumors · Lung Cancer · Breast Cancer
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by CTCAE v5.0 — 4; 4; 10; 12 Participants
Early Phase 1 N=20 Influence of Medication on Functional Connectivity
Prescription Drug Abuse (Not Dependent)
Primary: Change in Functional Connectivity Following Oxycodone Administration — 2.66; 4.55; .99; 1.60 z-score
N/A N=94 Acupuncture for Plantar Fasciosis in the Primary Care Setting
Plantar Fascitis
Primary: NPRS-11 — 3.8; 4.3; 3.7; 3.1 score on a scale
Phase 1 N=24 A Study in Healthy Men to Test How Different Doses of BI 474121 Are Taken up and How They Influence the Amount of a Molecular Messenger (cGMP) in the Spinal Fluid
Healthy
Primary: Maximum Exposure-related Change From Baseline (Calculated as Ratio) of Cyclic Guanosine Monophosphate (cGMP) in Cerebrospinal Fluid (CSF) — NA; NA; NA; NA maximum change…
Phase 2 N=47 A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis
Lupus Nephritis · Systemic Lupus Erythematosus
Primary: Phase 1b: Number of Patients Who Experienced at Least One Treatment-Related Treatment-Emergent Adverse Event — 7; 5; 11; 3 Participants
Phase 1 N=70 A Study in Healthy Men and Women Who Are Either Between 18 - 45 Years or Between 65 - 80 Years to Test How Different Doses of BI 474121 Are Tolerated
Healthy
Primary: Percentage of Participants With Drug-related Adverse Events — 40.0; 75.0; 50.0; 75.0 Percentage of participants
N/A N=15 Feasibility of Teleyoga for Treatment of Lyme Disease
Lyme Disease
Primary: Change of Pain Score From Baseline — 5.7; 4.8; 2.9; 4.6 score on a scale
Phase 1 N=18 Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants
Healthy
Primary: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Tepotinib — 25101; 16738 hours* nanograms per milliliter(h*ng/mL)
N/A N=81 Using Combined EEG and Non-invasive Brain Stimulation to Examine and Improve Reward Functioning in Opioid Use Disorder
Opioid-use Disorder
Primary: Reward Positivity — -5.2; -2.3; -4.4; -4.6 μV (microvolts)
Phase 1 N=83 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses
Healthy
Primary: Number of Young and Elderly Subjects With On-treatment Adverse Events by Treatment Group — 6; 3; 5; 6 Participants
Phase 1 N=25 Bintrafusp Alfa Combination Therapy in Participants With Cervical Cancer (INTR@PID 046)
Cervical Cancer
Primary: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0; 2; 0 Participants
N/A N=24 Weight Loss and Exercise To Improve Rheumatoid Arthritis Cardiovascular Risk
Rheumatoid Arthritis
Primary: Metabolic Syndrome Severity Z-score (MSSc) — -1.89; -1.82; -3.23; -3.49 Z-score (unitless) — p=<0.05
Phase 3 N=66 A Safety and Efficacy Study of Ligelizumab in the Treatment of CSU in Japanese Patients Inadequately Controlled With H1- Antihistamines
Chronic Spontaneous Urticaria
Primary: Safety and Tolerability of Ligelizumab 120 mg q4w Treatment for 12 Months — 53; 11; 0; 13 Participants